Michel Dewilde

Biography

Michel De Wilde joined the IDRI Board of Directors in October 2014. Currently serving as a consultant for the international vaccine community, Michel De Wilde was among the first to use recombinant DNA technology in the industry and has contributed to the discovery and development of a number of vaccines. From 2001 through 2013, De Wilde was Senior Vice President, Research & Development, at Sanofi Pasteur, the human vaccines division of Sanofi, where he supervised a broad portfolio of discovery and development projects, including the first Dengue vaccine that recently successfully completed phase 3 During his tenure at Sanofi Pasteur, De Wilde drove the development and licensure by the U.S. Food and Drug Administration of a number of products, including the first tetravalent meningococcal conjugate, the first prototype H5 pandemic vaccine and the first intradermal influenza vaccine, Intanza, which was also licensed by the European Medicines Agency. He also oversaw the licensure, under accelerated approval, of a new high-dose formulation of an influenza vaccine, which demonstrated superior efficacy to conventional vaccines in clinical trials. De Wilde was also instrumental in driving the acquisition of and defining the integration model for two biotech companies, Acambis and VaxDesign. Prior to joining Sanofi Pasteur, De Wilde was at SmithKline Beecham Biologicals (now GSK Vaccines) in Belgium. He joined the group in 1978 as a research scientist and subsequently held positions of increasing responsibility to become Vice President, Research & Development, heading a team active in all aspects of preclinical vaccine development.

Research Interest

preclinical vaccine development.